Patient Preference for Subcutaneous Versus Intravenous Administration with Every-6-Week Natalizumab (Tysabri
Extended interval dosing
Intravenous
Multiple sclerosis
NOVA
Natalizumab
Patient preference
Subcutaneous
Journal
Neurology and therapy
ISSN: 2193-8253
Titre abrégé: Neurol Ther
Pays: New Zealand
ID NLM: 101637818
Informations de publication
Date de publication:
24 Jul 2024
24 Jul 2024
Historique:
received:
03
04
2024
accepted:
04
07
2024
medline:
24
7
2024
pubmed:
24
7
2024
entrez:
24
7
2024
Statut:
aheadofprint
Résumé
Following NOVA (part 1) and the approval of the subcutaneous (SC) route of administration of natalizumab by the European Medicines Agency, an extension phase of the NOVA phase IIIb study (part 2) was initiated to collect patient preference data for SC versus intravenous (IV) dosing in patients receiving every-6-week (Q6W) dosing of natalizumab. This study was performed to evaluate patient preference for SC versus IV natalizumab administration and explore the efficacy, safety, and pharmacology characteristics of both routes of administration. In part 2, participants received natalizumab (Tysabri A total of 153 participants were randomized in NOVA part 2. Of 123 with patient preference data, 108 (87.8%) preferred the SC route of administration for natalizumab over the IV route; 102 (82.9%) specified "requires less time in the clinic" as the reason for the SC preference. In NOVA (part 2), most participants on Q6W dosing of natalizumab preferred SC administration versus IV administration. GOV: NCT03689972. INFOGRAPHIC.
Identifiants
pubmed: 39046635
doi: 10.1007/s40120-024-00647-0
pii: 10.1007/s40120-024-00647-0
doi:
Banques de données
ClinicalTrials.gov
['NCT03689972']
Types de publication
Journal Article
Langues
eng
Informations de copyright
© 2024. The Author(s).
Références
Jackson Y, Janssen E, Fischer R, et al. The evolving role of patient preference studies in health-care decision-making, from clinical drug development to clinical care management. Expert Rev Pharmacoecon Outcomes Res. 2019;19(4):383–96.
doi: 10.1080/14737167.2019.1612242
pubmed: 31070048
Tysabri (natalizumab) [prescribing information]. Biogen Inc. Cambridge.
FDA approves Tysabri. 2004. https://www.drugs.com/newdrugs/tysabri-approved-multiple-sclerosis-162.html . Accessed 31 Oct 2023
Simonsen CS, Flemmen H, Broch L, et al. Early high efficacy treatment in multiple sclerosis is the best predictor of future disease activity over 1 and 2 years in a Norwegian population-based registry. Front Neurol. 2021;12: 693017.
doi: 10.3389/fneur.2021.693017
pubmed: 34220694
pmcid: 8248666
Tysabri: EPAR—product information. 2022. https://www.ema.europa.eu/en/medicines/human/EPAR/tysabri#product-information-section . Accessed 1 Nov 2023
FDA Drug Safety Communication: risk of progressive multifocal leukoencephalopathy (PML) with the use of Tysabri (natalizumab). 2010. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fda-drug-safety-communication-risk-progressive-multifocal-leukoencephalopathy-pml-use-tysabri . Accessed 31 Oct 2023
Zhovtis Ryerson L, Foley J, Chang I, et al. Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing. Neurology. 2019;93(15):e1452–62.
Foley JF, Defer G, Ryerson LZ, et al. Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial. Lancet Neurol. 2022;21(7):608–19.
doi: 10.1016/S1474-4422(22)00143-0
pubmed: 35483387
Tysabri (natalizumab). 2021. https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-tysabri-x-116_en.pdf . Accessed 1 Nov 2023
Plavina T, Fox EJ, Lucas N, Muralidharan KK, Mikol D. A randomized trial evaluating various administration routes of natalizumab in multiple sclerosis. J Clin Pharmacol. 2016;56(10):1254–62.
doi: 10.1002/jcph.707
pubmed: 26835603
Trojano M, Ramió-Torrentà L, Grimaldi LM, et al. A randomized study of natalizumab dosing regimens for relapsing-remitting multiple sclerosis. Mult Scler. 2021;27(14):2240–53.
doi: 10.1177/13524585211003020
pubmed: 33821693
pmcid: 8597184
Gold R, Schmidt S, Motte J, et al. SISTER—subcutaneous: non-interventional, observational, prospective, German multi-center, open label study over 12 months for Tysabri patient preference. In: 38th Congress of the European Committee for treatment and research in multiple sclerosis (ECTRIMS 2022) 2022 26
Filippi M, Grimaldi L, Conte A, et al. Intravenous or subcutaneous natalizumab in patients with relapsing-remitting multiple sclerosis: investigation on efficiency and savings – the EASIER study. J Neurol. 2024;271(1):340–54.
doi: 10.1007/s00415-023-11955-0
pubmed: 37715789
Bittner B, Richter W, Schmidt J. Subcutaneous administration of biotherapeutics: an overview of current challenges and opportunities. BioDrugs. 2018;32(5):425–40.
doi: 10.1007/s40259-018-0295-0
pubmed: 30043229
pmcid: 6182494
Alten R, An Y, Kim DH, Yoon S, Peyrin-Biroulet L. Re-routing infliximab therapy: subcutaneous infliximab opens a path towards greater convenience and clinical benefit. Clin Drug Investig. 2022;42(6):477–89.
doi: 10.1007/s40261-022-01162-6
pubmed: 35657560
Zhovtis Ryerson L, Frohman TC, Foley J, et al. Extended interval dosing of natalizumab in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2016;87(8):885–9.
doi: 10.1136/jnnp-2015-312940
pubmed: 26917698
Clerico M, De Mercanti SF, Signori A, et al. Extending the interval of natalizumab dosing: is efficacy preserved? Neurotherapeutics. 2020;17(1):200–7.
doi: 10.1007/s13311-019-00776-7
pubmed: 31452081
Zhovtis Ryerson L, Naismith RT, Krupp LB, et al. No difference in radiologic outcomes for natalizumab patients treated with extended interval dosing compared with standard interval dosing: real-world evidence from MS PATHS. Mult Scler Relat Disord. 2022;58: 103480.
doi: 10.1016/j.msard.2021.103480
Zhovtis Ryerson L, Foley JF, Defer G, et al. Exploratory clinical efficacy and patient-reported outcomes from NOVA: a randomized controlled study of intravenous natalizumab 6-week dosing versus continued 4-week dosing for relapsing-remitting multiple sclerosis. Mult Scler Relat Disord. 2023;72: 104561.
doi: 10.1016/j.msard.2023.104561
Volkers A, Straatmijer T, Duijvestein M, et al. Real-world experience of switching from intravenous to subcutaneous vedolizumab maintenance treatment for inflammatory bowel diseases. Aliment Pharmacol Ther. 2022;56(6):1044–54.
doi: 10.1111/apt.17153
pubmed: 35869807
pmcid: 9540102
Muralidharan KK, Kuesters G, Plavina T, et al. Population pharmacokinetics and target engagement of natalizumab in patients with multiple sclerosis. J Clin Pharmacol. 2017;57(8):1017–30.
doi: 10.1002/jcph.894
pubmed: 28398628
Toorop AA, van Kempen ZLE, Steenhuis M, et al. Decrease of natalizumab drug levels after switching from intravenous to subcutaneous administration in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry. 2023;94(6):482–6.
doi: 10.1136/jnnp-2022-330467
pubmed: 36639226
Fox RJ, Cree BA, De Sèze J, et al. MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study. Neurology. 2014;82(17):1491–8.
doi: 10.1212/WNL.0000000000000355
pubmed: 24682966
pmcid: 4011468
Derfuss T, Kovarik JM, Kappos L, et al. α4-integrin receptor desaturation and disease activity return after natalizumab cessation. Neurol Neuroimmunol Neuroinflamm. 2017;4(5): e388.
doi: 10.1212/NXI.0000000000000388
pubmed: 28856176
pmcid: 5572051